摘要
为探讨阿尔茨海默病(AD)与甲状腺激素的关系和AD患者应用胆碱酯酶抑制剂治疗6个月后甲状腺激素水平的变化,将61例AD患者分为治疗组(27例,使用选择性胆碱酯酶抑制剂,连续治疗6个月)和未治疗组(34例),并以58名健康者作为对照组,分别于AD患者治疗前及治疗后第6个月检测血清FT3、FT4、TT3和TT4浓度。结果显示,①治疗前全部AD患者FT3、TT3浓度明显低于对照组(P<0.01,P<0.05);②AD患者中治疗组与未治疗组比较,治疗前两组各激素水平无差异(P>0.05),治疗组血清FT3、TT4水平6个月后和治疗前比较差异有显著性(P<0.01,P<0.05)。这提示甲状腺功能异常可能与AD发病有关,用胆碱酯酶抑制剂治疗后可上调甲状腺激素水平。
To investigate the changes of the thyroid hormone levels in patients with Alzheimer disease （AD） after six months treatment with cholinesterase inhibitor, the serum concentrations of FT3, FT4, TT3 and TT4 were determined in 61 patients with AD and 58 normal controis. The patients with AD were divided into treatment group which treated with selective cholinesterase inhibitors for six months （n= 27） and untreated group （n=34）. The results showed that the serum levels of FT3 and TT3 in AD group were significantly lower than those in normal control group （P〈0.01, P〈0.05）. There was significant difference in the concentration of FT3 between treated group and untreated group after 6 months （P〈0.01）. This study indicates that abnormal thyroid function in patient might be related to AD. The patients treated with cholinesterase inhibitor may up-regulate the levels of thyroid hormones.
出处
《标记免疫分析与临床》
CAS
2008年第2期93-95,共3页
Labeled Immunoassays and Clinical Medicine
